We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 38 of 123 for:    fibromyalgia | Recruiting, Not yet recruiting, Available Studies

Myofascial Release of Physiological Chains and Muscle Stretching in Patients With Fibromyalgia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03408496
Recruitment Status : Recruiting
First Posted : January 24, 2018
Last Update Posted : February 1, 2018
Information provided by (Responsible Party):
Nina Bretas Bittar Schulze, Universidade Federal de Pernambuco

Brief Summary:

Muscle stretching is a therapeutic technique commonly used by physiotherapists, but for the treatment of fibromyalgia it still has weak evidence to support its real effect. On the other hand, myofascial mobilization in the location of tender points, as it is the solution for the population, demonstrating effects on the improvement of the symptoms, but not yet achieving the minimal clinically important change. In this context, myofascial release guided by physiological chains, so far not studied, is presented as an alternative to improve pain and quality of life in patients with fibromyalgia because it acts in a global way and, probably, more effective.

This study evaluates the effect of myofascial release of the trunk physiological chains and muscle stretching on pain, quality of life and functional capacity of patients with fibromyalgia when compared to the control group.

Condition or disease Intervention/treatment
Fibromyalgia Other: Myofascial release Other: Muscle stretching Other: Control

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be allocated in 3 groups. The myofascial release group, muscle stretching group and control group.
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Myofascial Release of the Trunk Physiological Chains and Muscle Stretching on Pain, Quality of Life and Functional Capacity of Patients With Fibromyalgia: Randomized Controlled Clinical Trial
Actual Study Start Date : January 23, 2018
Estimated Primary Completion Date : November 21, 2018
Estimated Study Completion Date : January 25, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fibromyalgia
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Myofascial release
Eight consecutive weekly sessions lasting 40-45 minutes of myofascial release of the trunk physiological chains. The connective tissue of the flexion chain and the posterior static chain will be released. The myofascial release will be obtained through the mechanical effect produced by the friction of the therapist's hand with a surface of the patient's body, which is performed through "traces" executed with the fingers (thumb supported or middle finger on the indicator to achieve effect local) following as addressed chains. The release will be repeated until the feeling of local relaxation of the tissue.
Other: Myofascial release
Manual therapy
Experimental: Muscle Stretching
The muscle stretching protocol described by Bressan (2008) will be followed, which consists of 8 consecutive weekly sessions, lasting 40-45 minutes. In dorsal decubitus or sitting, the triceps surae, hamstring, gluteal, paravertebral, latissimocondyloideus, pectoral, trapezius and respiratory muscles will be stretched. The exercises will be performed in a series of five repetitions for 30 seconds.
Other: Muscle stretching
Muscle stretching
Active Comparator: Control
It will perform only the treatment prescribed by the responsable doctor, wich can be the use of drug and/or psychological treatment, and will be followed clinically by a rheumatologist during four medical appointments to monitor medication and follow in the analgesic's diary, according the standard procedure of attending the hospital where the patients will be recruited.
Other: Control
Medical appointment

Primary Outcome Measures :
  1. Pain intensity level change [ Time Frame: Baseline, after 4 weeks since the beginning of the treatment, after 8 weeks since the beginning of the treatment, follow-up (after 12 weeks since the beginning of the treatment) ]
    Self reported pain intensity measured by the Visual Analog Scale, wich ranges from 0 to 10, where 0 means absence of pain and 10 means the worst pain already felt

  2. Number of painful areas change [ Time Frame: Baseline, after 4 weeks since the beginning of the treatment, after 8 weeks since the beginning of the treatment, follow-up (after 12 weeks since the beginning of the treatment) ]
    Evaluated by the Widespread Pain Index

  3. Quality of life score change [ Time Frame: Baseline, after 4 weeks since the beginning of the treatment, after 8 weeks since the beginning of the treatment, follow-up (after 12 weeks since the beginning of the treatment) ]
    Evaluated by the Fibromyalgia Impact Questionnaire, wich evaluates aspects of functional capacity, work status, psychological disturbances and physical symptoms. The total score ranges from 0 to 100, where higher scores have a worst impact of fibromyalgia on quality of life and functional capacity.

Secondary Outcome Measures :
  1. Amount of analgesic ingested [ Time Frame: Up to 12 weeks ]
    Measured by the analgesic diary, wich is filled weekly

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmation of the diagnosis by rheumatologists according to the diagnostic criteria established by the American College of Rheumatology of 1990 and 2010.
  • Moderate to severe pain according to the Fibromyalgia Impact Questionnaire (≥ 4).
  • Patients classified as "sedentary" and "irregularly active" by the International Physical Activity Questionnaire.
  • Prescribed treatment (drug and/or psychological) stable in the last month before the selection.
  • Patients who live in the metropolitan area of Recife - Pernambuco, Brazil.

Exclusion Criteria:

  • Nonpharmacologic therapies, except for psychological treatment if prescribed by the doctor at the same time of the study.
  • Skin diseases.
  • Women who use intrauterine devices (IUD).
  • Pregnant women.
  • Patients with other associated rheumatic disease or with modified posture due to congenital anatomic alteration.
  • Severe decompensated comorbidities (cancer, thyroid disease and diabetes).
  • Infection, fever, hypotension, respiratory alterations limiting treatment.
  • Cardiovascular event in the previous year.
  • Presence of cardiac, renal or hepatic insufficiency.
  • Arterial or peripheral venous insufficiency.
  • Presence of a hypertrophic scar on the trunk.
  • Obesity grade 3.
  • Illiteracy.
  • Severe psychiatric illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03408496

Contact: Nina Schulze +5581999031656 nina.bretas@hotmail.com

Universidade Federal de Pernambuco Recruiting
Recife, Pernambuco, Brazil, 50740-560
Contact: Nina Schulze    5581999031656    nina.bretas@hotmail.com   
Sponsors and Collaborators
Universidade Federal de Pernambuco

Responsible Party: Nina Bretas Bittar Schulze, Principal Investigator, Universidade Federal de Pernambuco
ClinicalTrials.gov Identifier: NCT03408496     History of Changes
Other Study ID Numbers: NSchulze
First Posted: January 24, 2018    Key Record Dates
Last Update Posted: February 1, 2018
Last Verified: January 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Nina Bretas Bittar Schulze, Universidade Federal de Pernambuco:
Myofascial release
Manual therapy
Muscle stretching
Quality of life

Additional relevant MeSH terms:
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases